FDA Orange Book Data Files Updated, Giving Regulatory Teams Structured Access to TE Codes and Patent Records

Generic drug strategy and therapeutic equivalence assessments depend on the integrity and accessibility of FDA Orange Book data, and the agency's current data file architecture gives regulatory affairs teams several structured pathways to work with that information programmatically or in bulk. The Orange Book data files, updated monthly, are available as compressed ZIP downloads and through the openFDA API in JSON format, covering three core datasets: product listings, patent records, and exclusivity data.

The primary file, Products.txt, is ASCII text in tilde-delimited format and contains the fields most directly relevant to ANDA strategy: active ingredient, dosage form and route, NDA or ANDA application type, Therapeutic Equivalence (TE) codes, Reference Listed Drug (RLD) designation, and Reference Standard (RS) status. TE codes carry particular weight for QA and regulatory leads because they define whether a generic product is rated therapeutically equivalent to its innovator reference under 21 CFR Part 314, directly affecting substitutability determinations at the pharmacy level.

The Patent.txt file records patent numbers as submitted by NDA holders, expiry dates including applicable extensions, and drug substance and drug product flags for patents listed after August 18, 2003 on FDA Form 3542. These flags distinguish whether a listed patent claims the drug substance or the drug product formulation, a distinction that shapes Paragraph IV certification strategy for ANDA applicants. Exclusivity data, held in the third file, captures market exclusivity periods that can block or delay generic approval independent of patent status.

For teams conducting freedom-to-operate analyses or preparing ANDA submissions, the openFDA Orange Book API offers a searchable, machine-readable alternative to manual file downloads, with query options by active ingredient, proprietary name, applicant, or application number. Appendices A through C, available in PDF, provide product name indexes and uniform terminology references that support cross-referencing against internal regulatory databases.

The monthly update cadence means patent expiry dates, new RLD designations, and TE code assignments reflect relatively current agency determinations, though regulatory leads should verify critical data points directly against the FDA approval letter and the electronic Orange Book search interface before relying on downloaded files for submission-critical decisions.

Teams building or maintaining generic pipeline trackers should confirm their data pull schedules align with the monthly refresh cycle to avoid acting on stale patent expiry or exclusivity records.

Source: FDA via What's New: Drugs RSS Feed, August 6, 2026.